SCHEMBL824437

SCHEMBL824437

O=C(O)c1ccc2nc3n(c2c1)c1nc2ccc(C(=O)O)cc2n1c1nc2ccc(C(=O)O)cc2n31

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.49
FGFR1 P11362 1/20 0.47
KDM4E B2RXH2 5/20 0.45
NPC1 O15118 4/20 0.45
RAB9A P51151 4/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
ALDH1A1 P00352 3/20 0.45
HPGD P15428 3/20 0.45
GAA P10253 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
ACSS2 Q9NR19 1/20 0.45
HCAR3 P49019 2/20 0.44
HSP90AA1 P07900 1/20 0.44
ESR2 Q92731 1/20 0.44
HKDC1 Q2TB90 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
HSD17B10 Q99714 1/20 0.42
MAPT P10636 1/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL824415 0.93 HSD17B10 (0.48) TDP1FGFR1KDM4ENPC1RAB9A
SCHEMBL824420 0.93 HSD17B10 (0.48) TDP1FGFR1KDM4ENPC1RAB9A
SCHEMBL16488365 0.88 PDE2A (0.40) TDP1FGFR1KDM4ENPC1RAB9A
SCHEMBL824442 0.85 HSD17B10 (0.53) TDP1FGFR1KDM4ENPC1RAB9A
SCHEMBL4549640 0.80 TDP1 (0.42) TDP1FGFR1KDM4ENPC1RAB9A
SCHEMBL18247596 0.74 TDP1 (0.53) TDP1FGFR1KDM4ENPC1RAB9A
SCHEMBL31140562 0.74 TDP1 (0.49) TDP1FGFR1KDM4ENPC1RAB9A
SCHEMBL12036943 0.74 KMT2A (0.55) TDP1FGFR1KDM4ENPC1RAB9A
SCHEMBL14502336 0.74 KMT2A (0.55) TDP1FGFR1KDM4ENPC1RAB9A
SCHEMBL38664949 0.73 FGFR1 (0.41) TDP1FGFR1KDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2291703-B1 COLOR LIQUID CRYSTAL DISPLAY AND COMPENSATION PANEL CRYSOPTIX KK (JP) 2016-11-30 EP disclosed
US-8895118-B2 Negative dispersion retardation plate and achromatic circular polarizer CRYSOPTIX K.K. (JP) 2014-11-25 US disclosed
US-8895118-B2 Negative dispersion retardation plate and achromatic circular polarizer CRYSOPTIX K.K. (JP) 2014-11-25 US disclosed
US-8416376-B2 Compensated in-plane switching mode liquid crystal display CRYSOPTIX KK (JP) 2013-04-09 US disclosed
US-8416376-B2 Compensated in-plane switching mode liquid crystal display CRYSOPTIX KK (JP) 2013-04-09 US disclosed
US-20120113380-A1 NEGATIVE DISPERSION RETARDATION PLATE AND ACHROMATIC CIRCULAR POLARIZER CRYSOPTIX KK (JP) 2012-05-10 US disclosed
US-20120113380-A1 NEGATIVE DISPERSION RETARDATION PLATE AND ACHROMATIC CIRCULAR POLARIZER CRYSOPTIX KK (JP) 2012-05-10 US disclosed
US-8142863-B2 Color liquid crystal display and compensation panel Crysoptix, KK (JP) 2012-03-27 US disclosed
US-8142863-B2 Color liquid crystal display and compensation panel Crysoptix, KK (JP) 2012-03-27 US disclosed
US-7889297-B2 Liquid crystal display operating in a vertically aligned mode Crysoptix, KK (JP) 2011-02-15 US disclosed
US-7889297-B2 Liquid crystal display operating in a vertically aligned mode Crysoptix, KK (JP) 2011-02-15 US disclosed
US-20100279122-A1 Benzimidazole, Benzoxazole and Benzothiazole Derivatives, Optical Film Comprising them and Method of Producing thereof CRYSOPTIX KK (JP) 2010-11-04 US disclosed
US-20100279122-A1 Benzimidazole, Benzoxazole and Benzothiazole Derivatives, Optical Film Comprising them and Method of Producing thereof CRYSOPTIX KK (JP) 2010-11-04 US disclosed
US-20100149471-A1 Compensated In-Plane Switching Mode Liquid Crystal Display CRYSOPTIX KK (JP) 2010-06-17 US disclosed
US-20100149471-A1 Compensated In-Plane Switching Mode Liquid Crystal Display CRYSOPTIX KK (JP) 2010-06-17 US disclosed
US-20100118241-A1 Liquid Crystal Display Operating in a Vertically Aligned Mode CRYSOPTIX KK (JP) 2010-05-13 US disclosed
US-20100118241-A1 Liquid Crystal Display Operating in a Vertically Aligned Mode CRYSOPTIX KK (JP) 2010-05-13 US disclosed
US-20090268136-A1 Color Liquid Crystal Display and Compensation Panel CRYSOPTIX KK (JP) 2009-10-29 US disclosed
US-20090268136-A1 Color Liquid Crystal Display and Compensation Panel CRYSOPTIX KK (JP) 2009-10-29 US disclosed
WO-2008020211-A2 BENZIMIDAZOLE, BENZOXAZOLE AND BENZOTHIAZOLE DERIVATIVES, OPTICAL FILM COMPRISING THEM AND METHOD OF PRODUCTION THEREOF CRYSOPTIX K.K. (JP) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100279122-A1 Benzimidazole, Benzoxazole and Benzothiazole Derivatives, Optical Film Comprising them and Method of Producing thereof BMX, ABCG2, BRI3BP TDP1 3607/4885FGFR1 4040/4885KDM4E 1712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.